Background- Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.
https://carolinaurologicresearchcenter.com/wp-content/uploads/NEJM.jpg521625CURC/wp-content/uploads/logo-1.pngCURC2019-02-18 15:57:562019-02-18 16:05:26Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572